XML 89 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Selected Quarterly Financial Information (UNAUDITED)
 12 Months Ended
Dec. 31, 2013
Selected Quarterly Financial Information (UNAUDITED) [Abstract]  
Selected Quarterly Financial Information (UNAUDITED)
20. Selected Quarterly Financial Information (UNAUDITED)

 
 
First
Quarter
  
Second
Quarter
  
Third
Quarter
  
Fourth
Quarter
 
Year Ended December 31, 2013
 
  
  
  
 
Revenues, net
 
$
431,724
  
$
1,035,514
  
$
507,384
  
$
1,670,063
 
Acquired in-process research and development(1)
  
-
   
-
   
-
   
17,458,766
 
Operating expenses
  
8,811,633
   
9,151,965
   
10,709,337
   
13,504,740
 
Loss from operations
  
(8,379,909
)
  
(8,116,451
)
  
(10,201,953
)
  
(29,243,443
)
Net loss attributable to BioTime, Inc.(2)
  
(7,719,263
)
  
(7,549,765
)
  
(9,003,168
)
  
(19,612,314
)
 
                
Basic and diluted net loss per share
  
(0.15
)
  
(0.14
)
  
(0.16
)
  
(0.35
)
 
                
Year Ended December 31, 2012
                
Revenues, net
 
$
631,946
  
$
949,746
  
$
833,817
  
$
1,065,547
 
Operating expenses
  
6,547,486
   
7,029,077
   
6,780,375
   
8,124,795
 
Loss from operations
  
(5,915,540
)
  
(6,079,331
)
  
(5,946,558
)
  
(7,059,248
)
Net loss attributable to BioTime, Inc.
  
(4,973,342
)
  
(5,457,222
)
  
(4,958,014
)
  
(6,037,125
)
Basic and diluted net loss per share
  
(0.10
)
  
(0.11
)
  
(0.10
)
  
(0.12
)

(1)Includes IPR&D expenses related to intangible assets acquired by Asterias from Geron under the Asset Contribution Agreement.  IPR&D represents the value of incomplete research and development projects which Asterias intends to continue.  See Notes 2 and 15.
(2)
Net of $3,280,695 income tax benefits in fourth quarter.